STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1653 by analyst upside · 2026-09-14
RLAY
Relay Therapeutics, Inc.
Healthcare · Market Cap $4B · P/E 0x
ANALYST PRICE TARGET
+43.5%
implied upside to consensus target
Current Price $18.87
Consensus Target $27.08
Bull Target $32.0
Bear Target $20.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
10
Hold
0
Sell
0
52-Week Low $3.88
52-Week High $21.27
YTD Return +130.7%
FUNDAMENTALS
Market Cap $4B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.56
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $3.88
52-Week High $21.27
Current Price $18.87
Bear Target $20.0
Bull Target $32.0
● Now $18.87 ● Target $27.08
TRADING DATA
Avg Volume 3.2M
YTD Return +130.7%
Analyst Count 13
Consensus Buy
Upside to Target +43.5%
Last Updated 2026-09-14

ANALYST SUMMARY

Relay Therapeutics, Inc. (RLAY) is currently trading at $18.87 with a Wall Street consensus price target of $27.08, implying potential upside of 43.5% over the next 12 months. 13 analysts currently cover RLAY, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $32.0, while the most cautious has a target of $20.0.

RLAY operates in the Healthcare sector with a market capitalisation of $4B. The stock is up 130.7% year-to-date and is currently trading near the upper end of its 52-week range of $3.88 – $21.27.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for RLAY, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-20 31% win rate (48 calls)
JP Morgan - Reiterated
Overweight → Overweight 2026-08-14 43% win rate (7 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-10 Building track record
Barclays - Reiterated
Overweight → Overweight 2026-08-07 Building track record
Goldman Sachs - Reiterated
Buy → Buy 2026-07-21 Building track record
Canaccord Genuity ● Initiated
Buy 2026-07-16 Building track record
JP Morgan ● Initiated
Overweight 2026-07-08 43% win rate (7 calls)
Guggenheim - Reiterated
Buy → Buy 2026-05-26 62% win rate (8 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
64
out of 100
Coverage depth
20/30
Consensus clarity
17/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →